DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Bamco Inc. NY

Bamco Inc. NY decreased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 41.6% during the third quarter, according to its most recent filing with the SEC. The firm owned 564,854 shares of the medical device company's stock after selling 401,618 shares during the period. Bamco Inc. NY owned 0.14% of DexCom worth $37,868,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of DexCom in the 2nd quarter worth $25,000. Sachetta LLC grew its position in shares of DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company's stock worth $27,000 after buying an additional 171 shares during the last quarter. Riverview Trust Co raised its stake in shares of DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock worth $31,000 after acquiring an additional 232 shares in the last quarter. DT Investment Partners LLC boosted its stake in DexCom by 492.2% in the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company's stock valued at $43,000 after acquiring an additional 315 shares in the last quarter. Finally, RPg Family Wealth Advisory LLC purchased a new position in DexCom in the third quarter worth $57,000. Institutional investors own 97.75% of the company's stock.

Insider Activity

In other news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company's stock, valued at $18,318,872.25. This represents a 0.28 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. The trade was a 0.56 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,431 shares of company stock worth $399,319 over the last three months. Insiders own 0.30% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on DXCM shares. Stifel Nicolaus upped their price objective on shares of DexCom from $90.00 to $100.00 and gave the company a "buy" rating in a report on Friday, August 23rd. Piper Sandler reiterated an "overweight" rating and set a $90.00 price objective on shares of DexCom in a research note on Monday, August 26th. Wells Fargo & Company upped their target price on DexCom from $80.00 to $90.00 and gave the company an "overweight" rating in a research report on Friday, October 25th. Robert W. Baird boosted their price target on DexCom from $80.00 to $82.00 and gave the company a "neutral" rating in a research note on Monday, August 5th. Finally, Oppenheimer dropped their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $104.59.

DexCom Price Performance

Shares of NASDAQ:DXCM traded up $0.74 during trading on Tuesday, reaching $80.05. The stock had a trading volume of 745,356 shares, compared to its average volume of 3,904,438. The business has a fifty day moving average price of $71.58 and a 200-day moving average price of $87.18. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The stock has a market cap of $31.27 billion, a PE ratio of 47.49, a PEG ratio of 2.38 and a beta of 1.12.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.